The breast cancer screening was valued at US$ 4,638.63 million in 2019 and is projected to reach US$ 6,209.25 million by 2027; it is expected to grow at a CAGR of 4.8% from 2020 to 2027.
The growing prevalence of breast cancer and increasing investments in breast cancer management are the major factors driving the breast cancer screening market. However, the high cost of breast cancer screening is a chief factor limiting the market growth. Breast cancer is among the prime causes of deaths in the world, and it is profoundly affecting the quality of life. Thus, it acts as a burden on society if not diagnosed and treated on time. As per the estimations by the American Cancer Society, it is the most common type of cancer in the US as it caused morbidity in ~234,087 people, leading to 41,904 deaths in 2018. Further, ~276,480 new cases are expected in the country in 2020. As per the Globocan 2019 report, in Germany, the total number of breast cancer cases in 2018 was 71,888, which further led to ~19,376 deaths in that years. Further, as per the Globocan report, in 2018, there were ~367,900 new cases of breast cancer and 97,972 deaths due to the same in China. In India, NGOs, government agencies, and charity organizations are emphasizing on breast cancer awareness among population to promote early detection, provide comprehensive treatment module, and extend support for breast cancer management. As per the Globocan report estimation, in 2018, India reported ~162,468 new breast cancer cases, with 87,090 deaths due to the same.
The global breast cancer screening market has been segmented on the basis of test type and end user. The breast cancer screening market, by test type, has been segmented into blood marker tests, imaging test, genetic test, and immunohistochemistry test. The imaging test segment held the largest share of the market in 2019, and it is also anticipated to register the highest CAGR in the market during the forecast period. Based on end user, the breast cancer screening has been segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitals segment held the largest share of the market in 2019 and is expected to register fastest CAGR during the forecast period.
A few of the essential primary and secondary sources referred to during the preparation of the report are Food and Drug Administration, World Health Organization (WHO), Organization for Economic Co-operation and Development, and National Cancer Foundation.
Reasons to Buy
The growing prevalence of breast cancer and increasing investments in breast cancer management are the major factors driving the breast cancer screening market. However, the high cost of breast cancer screening is a chief factor limiting the market growth. Breast cancer is among the prime causes of deaths in the world, and it is profoundly affecting the quality of life. Thus, it acts as a burden on society if not diagnosed and treated on time. As per the estimations by the American Cancer Society, it is the most common type of cancer in the US as it caused morbidity in ~234,087 people, leading to 41,904 deaths in 2018. Further, ~276,480 new cases are expected in the country in 2020. As per the Globocan 2019 report, in Germany, the total number of breast cancer cases in 2018 was 71,888, which further led to ~19,376 deaths in that years. Further, as per the Globocan report, in 2018, there were ~367,900 new cases of breast cancer and 97,972 deaths due to the same in China. In India, NGOs, government agencies, and charity organizations are emphasizing on breast cancer awareness among population to promote early detection, provide comprehensive treatment module, and extend support for breast cancer management. As per the Globocan report estimation, in 2018, India reported ~162,468 new breast cancer cases, with 87,090 deaths due to the same.
The global breast cancer screening market has been segmented on the basis of test type and end user. The breast cancer screening market, by test type, has been segmented into blood marker tests, imaging test, genetic test, and immunohistochemistry test. The imaging test segment held the largest share of the market in 2019, and it is also anticipated to register the highest CAGR in the market during the forecast period. Based on end user, the breast cancer screening has been segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitals segment held the largest share of the market in 2019 and is expected to register fastest CAGR during the forecast period.
A few of the essential primary and secondary sources referred to during the preparation of the report are Food and Drug Administration, World Health Organization (WHO), Organization for Economic Co-operation and Development, and National Cancer Foundation.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the breast cancer screening market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global breast cancer screening market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
2. Breast Cancer Screening Market - Key Takeaways
3. Research Methodology
4. Breast Cancer Screening - Market Landscape
5. Breast Cancer Screening- Key Market Dynamics
6. Breast Cancer Screening Market - Global Analysis
7. Breast Cancer Screening Market Analysis - By Test Type
8. Breast Cancer Screening Market - By End User
9. Breast Cancer Screening Market - Geographic Analysis
10. Impact Of COVID-19 Pandemic On Global Breast Cancer Screening Market
11. Breast Cancer Screening Market -Industry Landscape
12. Breast Cancer Screening Market - Key Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Koninklijke Philips N.V..
- Hologic, Inc.
- BD
- Myriad Genetics, Inc.
- Siemens Healthcare GMBH
- Exact Sciences Corporation
- Oncocyte Corporation
- POC Medical Systems
- Danaher
- GE